Weight Gain and Antipsychotics
J Clin Psychiatry 2005;66(7):950-951 [letter]
© Copyright 2016 Physicians Postgraduate Press, Inc.
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
The recent (November 2004) Commentary by Kane
provides readers with a comprehensive overview of the
current situation with regard to the controversy surrounding
the association of adverse metabolic effects with atypical antipsychotic
drugs. The discussion reported in the Commentary
was a response to a recently published consensus statement,2
as well as the U.S. Food and Drug Administration’s suggested
changes to labeling, and was intended to advise clinicians how
these recommendations may affect their clinical practice.
The panel of experts correctly identify the important areas
of uncertainty related to this topic, and they highlight the need
for further rigorous studies designed to examine the differential
effects of individual atypical agents.